Protagonist Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 38.46 million compared to USD 41.04 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.84 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to USD 0.84 a year ago.
For the six months, net loss was USD 72.19 million compared to USD 61.97 million a year ago. Basic loss per share from continuing operations was USD 1.34 compared to USD 1.27 a year ago. Diluted loss per share from continuing operations was USD 1.34 compared to USD 1.27 a year ago.